Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

November 14, 2006 16:52 ET

Holmes Biopharma-Business Proposal Activity Approaches Four Million USD

SCOTTSDALE, ARIZONA--(CCNMatthews - Nov. 14, 2006) - Holmes Biopharma, Inc. (OTCBB:HLMB) announced that its clinical research subsidiary, Qualia Clinical Research Service Inc ("Qualia") has outstanding proposal bids approaching a value of approximately $4,000,000 US.

The business development team continues to spark great interest from the biopharmaceutical industry for our Phase 1 operation in Omaha, Nebraska. Qualia has close to $1,000,000 US in signed contracts this year.

"This is tremendous level of activity in this business and puts us solidly on track to meet and exceed our budget for the first year of operations," stated Sohail Khattak, President and CEO of Qualia.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information